Nuwellis Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-0.14 (-3.00 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume74,671 shs
Average Volume467,323 shs
Market Capitalization$27.35 million
P/E RatioN/A
Dividend YieldN/A

Receive CHFS News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter.

Nuwellis logo

About Nuwellis

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.70 out of 5 stars

Medical Sector

317th out of 2,099 stocks

Electromedical Equipment Industry

7th out of 62 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Nuwellis (NASDAQ:CHFS) Frequently Asked Questions

Is Nuwellis a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuwellis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Nuwellis stock.
View analyst ratings for Nuwellis
or view top-rated stocks.

What stocks does MarketBeat like better than Nuwellis?

Wall Street analysts have given Nuwellis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nuwellis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Nuwellis' earnings last quarter?

Nuwellis, Inc. (NASDAQ:CHFS) posted its quarterly earnings data on Monday, March, 1st. The company reported ($1.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.91) by $0.34. The company earned $2.04 million during the quarter. Nuwellis had a negative trailing twelve-month return on equity of 173.61% and a negative net margin of 254.26%.
View Nuwellis' earnings history

When did Nuwellis' stock split? How did Nuwellis' stock split work?

Shares of Nuwellis reverse split on the morning of Friday, October 13th 2017. The 1-20 reverse split was announced on Thursday, October 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 12th 2017. An investor that had 100 shares of Nuwellis stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for CHFS?

1 analysts have issued 12 month price objectives for Nuwellis' shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Nuwellis' stock price to reach $20.00 in the next year. This suggests a possible upside of 341.5% from the stock's current price.
View analysts' price targets for Nuwellis
or view top-rated stocks among Wall Street analysts.

Who are Nuwellis' key executives?

Nuwellis' management team includes the following people:
  • Nestor Jaramillo, President, Chief Executive Officer, CFO & Director
  • Vitaliy Epshteyn, Senior Vice President-Operations & Engineering
  • David Lerner, Chief Technology Officer
  • Thomas P. Lynch, Secretary, Chief Legal & Compliance Officer
  • Laurent Duhoux, Vice President-International Business Development

Who are some of Nuwellis' key competitors?

What other stocks do shareholders of Nuwellis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nuwellis investors own include Biocept (BIOC), Immutep (IMMP), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Zosano Pharma (ZSAN), Avinger (AVGR), Co-Diagnostics (CODX), iBio (IBIO), Inovio Pharmaceuticals (INO) and Onconova Therapeutics (ONTX).

What is Nuwellis' stock symbol?

Nuwellis trades on the NASDAQ under the ticker symbol "CHFS."

What is Nuwellis' stock price today?

One share of CHFS stock can currently be purchased for approximately $4.53.

How much money does Nuwellis make?

Nuwellis has a market capitalization of $27.35 million and generates $5.51 million in revenue each year. The company earns $-18,110,000.00 in net income (profit) each year or ($279.28) on an earnings per share basis.

How many employees does Nuwellis have?

Nuwellis employs 66 workers across the globe.

What is Nuwellis' official website?

The official website for Nuwellis is

Where are Nuwellis' headquarters?

Nuwellis is headquartered at 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN, 55344.

How can I contact Nuwellis?

Nuwellis' mailing address is 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN, 55344. The company can be reached via phone at (952) 345-4200 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.